CORT
Corcept Therapeutics Incorporated
121.20$
+2.2%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.6% | +8.4% | +11.6% | +11.4% | -0.4% | -13.6% | +23.7% | +6.8% | -2.7% | -18.4% | +55.3% | – | |
| – | +14.1% | +35.1% | -0.4% | +13.6% | +3.1% | -18.7% | +42.9% | +33.9% | -44.6% | +13.3% | +40.9% | – | |
| – | +9.5% | +8.0% | +11.8% | +11.4% | -0.4% | -13.5% | +23.4% | +6.3% | -1.7% | -18.8% | +55.6% | – | |
| – | +20.2% | +6.9% | +0.4% | +1.0% | +18.5% | -13.6% | -0.4% | +13.8% | -5.8% | +2.2% | -18.7% | – | |
| – | +4.2% | +19.3% | +19.0% | +10.2% | +13.1% | +8.7% | +14.5% | +19.4% | +5.0% | +11.6% | +7.9% | – | |
| – | +12.2% | +12.7% | +9.5% | +5.9% | +15.5% | -1.5% | +8.5% | +17.3% | +1.2% | +8.5% | -0.4% | – | |
| – | +1.6% | -6.8% | +20.7% | +30.9% | -45.8% | -86.5% | +680.9% | -61.7% | -56.1% | -1,205.4% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.2% | -4.9% | +18.9% | +27.3% | -39.6% | -69.9% | +229.5% | -51.9% | -35.0% | -551.2% | – | – | |
| – | +8.9% | +32.6% | -15.5% | -6.2% | -78.8% | -1,000.2% | – | – | – | – | – | – | |
| – | -0.1% | -11.5% | +27.8% | +31.6% | -34.9% | -32.4% | +71.1% | -44.0% | +23.5% | -228.5% | – | – | |
| – | +1.9% | -6.1% | +19.2% | +27.7% | -39.3% | -68.9% | +219.1% | -51.1% | -33.9% | -524.5% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.